| Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron G Regev-Yochay, T Gonen, M Gilboa, M Mandelboim, V Indenbaum, ... New England Journal of Medicine 386 (14), 1377-1380, 2022 | 436 | 2022 |
| Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi, P Wung, N Patel, ... The Lancet Respiratory Medicine 9 (5), 522-532, 2021 | 280 | 2021 |
| Durability of immune response after COVID-19 booster vaccination and association with COVID-19 omicron infection M Gilboa, G Regev-Yochay, M Mandelboim, V Indenbaum, K Asraf, ... JAMA network open 5 (9), e2231778-e2231778, 2022 | 117 | 2022 |
| Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose Y Lustig, T Gonen, L Meltzer, M Gilboa, V Indenbaum, C Cohen, S Amit, ... Nature Immunology 23 (6), 940-946, 2022 | 101 | 2022 |
| Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study M Layan, M Gilboa, T Gonen, M Goldenfeld, L Meltzer, A Andronico, ... American journal of epidemiology 191 (7), 1224-1234, 2022 | 70 | 2022 |
| Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a … G Regev-Yochay, Y Lustig, G Joseph, M Gilboa, N Barda, I Gens, ... The Lancet Microbe 4 (5), e309-e318, 2023 | 69 | 2023 |
| Six-month follow-up after a fourth BNT162b2 vaccine dose M Canetti, N Barda, M Gilboa, V Indenbaum, K Asraf, T Gonen, ... New England Journal of Medicine 387 (22), 2092-2094, 2022 | 53 | 2022 |
| 4th dose COVID mRNA vaccines’ immunogenicity & efficacy against omicron VOC G Regev-Yochay, T Gonen, M Gilboa, M Mandelboim, V Indenbaum, ... MedRxiv, 2022.02. 15.22270948, 2022 | 43 | 2022 |
| Universal screening for Clostridioides difficile in a tertiary hospital: risk factors for carriage and clinical disease E Meltzer, G Smollan, A Huppert, R Fluss, I Tal, M Gilboa, ... Clinical Microbiology and Infection 25 (9), 1127-1132, 2019 | 38 | 2019 |
| COVID-19 vaccination and BA. 1 breakthrough infection induce neutralising antibodies which are less efficient against BA. 4 and BA. 5 Omicron variants, Israel, March to June 2022 L Kliker, N Zuckerman, N Atari, N Barda, M Gilboa, I Nemet, ... Eurosurveillance 27 (30), 2200559, 2022 | 34 | 2022 |
| Factors associated with protection from SARS-CoV-2 omicron variant infection and disease among vaccinated health care workers in Israel M Gilboa, T Gonen, N Barda, S Cohn, V Indenbaum, Y Weiss-Ottolenghi, ... JAMA network open 6 (5), e2314757-e2314757, 2023 | 32 | 2023 |
| Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up M Canetti, N Barda, M Gilboa, V Indenbaum, M Mandelboim, T Gonen, ... Nature Communications 13 (1), 7711, 2022 | 31 | 2022 |
| Early immunogenicity and safety of the third dose of BNT162b2 messenger RNA coronavirus disease 2019 vaccine among adults older than 60 years: real-world experience M Gilboa, M Mandelboim, V Indenbaum, Y Lustig, C Cohen, G Rahav, ... The Journal of Infectious Diseases 225 (5), 785-792, 2022 | 30 | 2022 |
| Environmental shedding of toxigenic Clostridioides difficile by asymptomatic carriers: a prospective observational study M Gilboa, E Houri-Levi, C Cohen, I Tal, C Rubin, O Feld-Simon, A Brom, ... Clinical Microbiology and Infection 26 (8), 1052-1057, 2020 | 30 | 2020 |
| Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review M Gilboa, G Bornstein, I Ben-Zvi, C Grossman Rheumatology international 40, 663-669, 2020 | 26 | 2020 |
| Saccharin increases fasting blood glucose but not liver insulin resistance in comparison to a high fructose-fed rat model A Leibowitz, A Bier, M Gilboa, E Peleg, I Barshack, E Grossman Nutrients 10 (3), 341, 2018 | 25 | 2018 |
| The association between prebooster vaccination antibody levels and the risk of severe acute respiratory syndrome coronavirus 2 infection N Barda, M Canetti, M Gilboa, K Asraf, V Indenboim, Y Weiss-Ottolenghi, ... Clinical Infectious Diseases 76 (7), 1315-1317, 2023 | 22 | 2023 |
| Early Immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience M Gilboa, M Mandelboim, V Indenbaum, Y Lustig, C Cohen, G Rahav, ... J Infect Dis 5, 1-10, 2021 | 20 | 2021 |
| Coronavirus disease 2019 (COVID-19) vaccination uptake among healthcare workers M Gilboa, I Tal, EG Levin, S Segal, A Belkin, T Zilberman-Daniels, A Biber, ... Infection Control & Hospital Epidemiology 43 (10), 1433-1438, 2022 | 19 | 2022 |
| Screening for Asymptomatic Clostridioides difficile Carriage Among Hospitalized Patients: A Narrative Review M Gilboa, N Baharav, E Melzer, G Regev-Yochay, D Yahav Infectious Diseases and Therapy 12 (9), 2223-2240, 2023 | 6 | 2023 |
